Concord Biotech Limited (CONCORDBIO) — Financial Flexibility Index
Concord Biotech Limited (CONCORDBIO) has a Financial Flexibility Index of 1.62x as of March 2025. Free cash flow of Rs3.59 Billion (operating CF Rs2.47 Billion minus capex Rs1.11 Billion) represents 2% of total liabilities (Rs2.22 Billion). Check cash flow reinvestment rate of Concord Biotech Limited to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Concord Biotech Limited Financial Flexibility Index (2020–2025)
Historical Financial Flexibility Index trend for Concord Biotech Limited across 6 annual periods. For the full cash flow conversion analysis, see Concord Biotech Limited (CONCORDBIO) cash conversion ratio.
Annual Financial Flexibility Index for Concord Biotech Limited (2020–2025)
Year-by-year free cash flow to debt coverage for Concord Biotech Limited. Explore CONCORDBIO operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (INR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.62x | Rs3.59 Billion | Rs2.47 Billion | Rs2.22 Billion | ▼ -19.8% |
| 2024 | 2.02x | Rs3.51 Billion | Rs2.65 Billion | Rs1.74 Billion | ▲ +15.5% |
| 2023 | 1.75x | Rs3.91 Billion | Rs2.46 Billion | Rs2.24 Billion | ▲ +0.8% |
| 2022 | 1.73x | Rs3.63 Billion | Rs2.07 Billion | Rs2.10 Billion | ▼ -14.5% |
| 2021 | 2.03x | Rs3.71 Billion | Rs1.67 Billion | Rs1.83 Billion | ▲ +11.1% |
| 2020 | 1.82x | Rs3.10 Billion | Rs1.55 Billion | Rs1.70 Billion | — |